{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-097153","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.590503+00:00","generated_at":"2026-05-17T04:36:54.447712+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Gain Therapeutics reports positive Phase 1b data for GT-02287 in Parkinson's disease","bullets":["GT-02287 safe and well-tolerated after 90 days; no serious adverse events.","Transient liver enzyme increases normalized with ongoing dosing.","Mean UPDRS Part II and III scores improved at Day 90, suggesting disease-slowing effect.","Plasma PK consistent across 14 participants, within therapeutic range.","DMC recommended continuation; Australian authorities approved 12-month extension."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-097153","json":"https://secwatch.observer/filing/0001104659-25-097153.json","markdown":"https://secwatch.observer/filing/0001104659-25-097153.md","text":"https://secwatch.observer/filing/0001104659-25-097153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925097153/0001104659-25-097153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465925097153/tm2528094d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:36:54.447712+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}